SCHEMBL984487

SCHEMBL984487

CCc1nc2cc(N)cnc2[nH]1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.41
HTT P42858 1/20 0.41
DDAH1 O94760 1/20 0.40
TNKS2 Q9H2K2 1/20 0.36
ADORA1 P30542 2/20 0.33
MAPT P10636 3/20 0.33
KDM4E B2RXH2 2/20 0.33
ADORA3 P0DMS8 1/20 0.32
ADORA2A P29274 1/20 0.32
FGFR3 P22607 1/20 0.32
ABL1 P00519 1/20 0.32
RET P07949 1/20 0.32
KDR P35968 1/20 0.32
CDK7 P50613 1/20 0.32
CDK5 Q00535 1/20 0.32
PRKAA1 Q13131 1/20 0.32
AURKB Q96GD4 1/20 0.32
CLK4 Q9HAZ1 1/20 0.32
PKM P14618 2/20 0.32
MEN1 O00255 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3590092 0.83 TDP1 (0.39) MAPTKDM4EPKMMEN1KMT2A
SCHEMBL12670573 0.81 GAA (0.42) GAAHTTDDAH1TNKS2ADORA1
SCHEMBL2721703 0.79 GAA (0.41) GAAHTTDDAH1TNKS2ADORA1
SCHEMBL986294 0.77 ALDH1A1 (0.37) GAATNKS2MAPTKDM4EFGFR3
SCHEMBL14347230 0.76 PDE2A (0.39) GAAHTTDDAH1KDM4EFGFR3
SCHEMBL984741 0.75 MAPT (0.36) GAAMAPTKDM4EPKMTDP1
SCHEMBL13072328 0.75 GAA (0.50) GAAHTTDDAH1TNKS2ADORA1
SCHEMBL5062600 0.75 DDAH1 (0.42) GAAHTTDDAH1TNKS2ADORA1
SCHEMBL12309220 0.74 MEN1 (0.42) GAAHTTDDAH1TNKS2MAPT
SCHEMBL986239 0.74 GRIN1 (0.47) GAAMAPTFGFR3CYP1A2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2265609-B1 IMDIZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS ARRAY BIOPHARMA INC (US) 2012-09-05 EP disclosed
US-20110003809-A1 IMIDAZO [4,5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS ARRAY BIOPHARMA INC. 2011-01-06 US disclosed
EP-2265609-A1 IMDIZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS Array Biopharma, Inc. (US) 2010-12-29 EP disclosed
WO-2009111277-A9 IMIDAZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS ARRAY BIOPHARMA INC. (US) 2009-12-30 WO disclosed
WO-2009111277-A1 IMDIZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS ARRAY BIOPHARMA INC. (US) 2009-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003809-A1 IMIDAZO [4,5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS BRAF, RAF1, ARAF GAA 3201/4885HTT 4873/4885DDAH1 2822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.